Web Desc
Engineering the Genome
joint with Emerging Cellular Therapies: Cancer and Beyond
Organizer(s): Vic Myer and Erik Sontheimer
Date: February 08 - 12, 2020
Location: Fairmont Banff Springs, Banff, AB, Canada
Sponsored by Editas Medicine and Novo Nordisk A/S
For important information on the coronavirus, please click here
Summary of Meeting:
Genome editing is already transforming biological science and promises to do the same for human medicine. Technological capabilities are advancing rapidly and there are expected to be more than 30 genome editing therapies in clinical development by 2020. It is therefore important that practitioners in both academia and industry have the opportunity to learn about the latest improvements and applications. This conference will bridge that gap and provide an ideal environment for scientific exchange. In addition, participants will be educated on the growing roster and utility of genome engineering platforms. There will be sessions on genome editing’s clinical advancements and the evolution of thinking in the field regarding translational sciences. This meeting is being paired with Emerging Cellular Therapies so that participants can come together with researchers who focus on cell-based therapies. Therefore, we anticipate attendees will have a greater awareness of the full range of genome engineering tools, both established and emerging and knowledge of best practices and pitfalls in clinical advancement.
Scholarship Deadline: October 29 2019
Discounted Abstract Deadline: October 29 2019
Abstract Deadline: November 6 2019
Discounted Registration Deadline: December 10 2019
Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.


Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Editas MedicineNovo Nordisk A/S
We gratefully acknowledge additional support from these exhibitors at this conference:
10x GenomicsBEX CO., LTD.Cellecta, Inc.Integrated DNA TechnologiesMilliporeSigmaSynthego
We gratefully acknowledge additional support for this conference from:
AgilentAldevron, LLCAmerican Society of Gene & Cell Therapy (ASGCT)IlluminaIntellia TherapeuticsNew England Biolabs, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Illumina

Intellia Therapeutics

Sangamo Therapeutics, Inc.
Keystone Symposia thanks the following Donors for their support of $2,500 - $4,999.
Illumina
We gratefully acknowledge the generous grant for this conference provided by:

National Center for Advancing Translational Sciences (NCATS)
Grant No. 1R13TR003025-01
Funding for this conference was made possible (in part) by 1R13TR003025-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. This award reflects support from the NIH Common Fund Somatic Cell Genome Editing (SCGE) program in the amount of $22,200 total costs.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Saturday, February 08 | 4:00PM - 8:00PM
Arrival and Registration
Room: Van Horne Foyer


Saturday, February 08 | 6:00PM - 8:00PM
Welcome Mixer
Room: Van Horne Foyer
No registration fees are used to fund alcohol served at this function.

Sunday, February 09 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Sunday, February 09 | 8:00AM - 9:30AM
Welcome and Keynote Session (Joint)
Room: Van Horne A/B

Speaker 1 of 5
* Vic E. Myer, Atlas Ventures, USA

Sunday, February 09 | 8:00AM - 9:30AM
Welcome and Keynote Session (Joint)
Room: Van Horne A/B

Speaker 2 of 5
* Crystal L. Mackall, Stanford University, USA

Sunday, February 09 | 8:00AM - 9:30AM
Welcome and Keynote Session (Joint)
Room: Van Horne A/B

Speaker 3 of 5
Jennifer A. Doudna, HHMI/University of California, Berkeley, USA
Genome Editing with CRISPR-Cas Systems: Challenges and Opportunities in a New Era of Biology

Sunday, February 09 | 8:00AM - 9:30AM
Welcome and Keynote Session (Joint)
Room: Van Horne A/B

Speaker 4 of 5
Carl H. June, University of Pennsylvania, USA
Updates with Engineered T Cells

Sunday, February 09 | 8:00AM - 9:30AM
Welcome and Keynote Session (Joint)
Room: Van Horne A/B


Coffee Break

Sunday, February 09 | 9:50AM - 12:00PM
Biochemistry, Biophysics and New Enzymes
Room: Van Horne C

Speaker 1 of 5
Kira S. Makarova, National Center for Biotechnology Information, USA
In silico Discovery of New Defense Systems

Sunday, February 09 | 9:50AM - 12:00PM
Biochemistry, Biophysics and New Enzymes
Room: Van Horne C

Speaker 2 of 5
* Erik Sontheimer, University of Massachusetts Medical School, USA
RNA-Guided RNA/DNA Cleavage by CRISPR-Cas Systems

Sunday, February 09 | 9:50AM - 12:00PM
Biochemistry, Biophysics and New Enzymes
Room: Van Horne C

Speaker 3 of 5
Ilya J. Finkelstein, University of Texas at Austin, USA
Massively-Parallel Profiling of Natural and Engineered High-Fidelity CRISPR Nucleases

Sunday, February 09 | 9:50AM - 12:00PM
Biochemistry, Biophysics and New Enzymes
Room: Van Horne C

Speaker 4 of 5
Ervin Welker, Research Center of Natural Sciences, Hungary
Short Talk: Ranking between Increased Fidelity SpCas9 Nucleases and Target Sites

Sunday, February 09 | 9:50AM - 12:00PM
Biochemistry, Biophysics and New Enzymes
Room: Van Horne C

Speaker 5 of 5
Garrett R. Rettig, Integrated DNA Technologies, USA
Short Talk: Engineered A.s. and L.b. Cas12a (Cpf1) Variants with Enhanced Activity

Sunday, February 09 | 9:50AM - 12:00PM
Genetically Engineered T Cell Therapies for Cancer: Results
from the Clinic
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 1 of 6
* Chiara Bonini, Ospedale San Raffaele, Italy


Sunday, February 09 | 9:50AM - 12:00PM
Genetically Engineered T Cell Therapies for Cancer: Results
from the Clinic
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 2 of 6
Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA
CAR T Cells for Solid Tumors


Sunday, February 09 | 9:50AM - 12:00PM
Genetically Engineered T Cell Therapies for Cancer: Results
from the Clinic
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 3 of 6
Yvonne Y. Chen, University of California, Los Angeles, USA
Synthetic Biology to Engineer More Potent CAR T Cells


Sunday, February 09 | 9:50AM - 12:00PM
Genetically Engineered T Cell Therapies for Cancer: Results
from the Clinic
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 4 of 6
Kristen Hege, Celgene, USA
Clinical Development of BCMA Targeted Immunotherapies in Multiple Myeloma


Sunday, February 09 | 9:50AM - 12:00PM
Genetically Engineered T Cell Therapies for Cancer: Results
from the Clinic
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 5 of 6
Brooke Prinzing, St. Jude Children's Research Hospital, USA
Short Talk: Chimeric Antigen Receptors with a MyD88 and CD40 Costimulatory Endodomain Endow T Cells with Superior Antitumor Activity


Sunday, February 09 | 9:50AM - 12:00PM
Genetically Engineered T Cell Therapies for Cancer: Results
from the Clinic
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 6 of 6
Evan William Weber, Stanford University, USA
Short Talk: The Src Kinase Inhibitor, Dasatinib, Enhances CAR-T Cell Potency by Mitigating T Cell Exhaustion


Sunday, February 09 | 12:00PM - 5:00PM
On Own for Lunch


Sunday, February 09 | 12:00PM - 1:00PM
Poster Setup
Room: Mezzanine 2


Sunday, February 09 | 1:00PM - 10:00PM
Poster Viewing
Room: Mezzanine 2


Sunday, February 09 | 2:30PM - 4:30PM
Panel: Ethics of Genome Editing
Room: Van Horne C

Speaker 1 of 5
* Tim Hunt, Editas Medicine, USA
Ethics of Genome Editing: Framing the Discussion

Sunday, February 09 | 2:30PM - 4:30PM
Panel: Ethics of Genome Editing
Room: Van Horne C

Speaker 2 of 5
Fyodor D. Urnov, University of California, Berkeley, USA

Sunday, February 09 | 2:30PM - 4:30PM
Panel: Ethics of Genome Editing
Room: Van Horne C

Speaker 3 of 5
Kathy K. Niakan, Francis Crick Institute, UK

Sunday, February 09 | 2:30PM - 4:30PM
Panel: Ethics of Genome Editing
Room: Van Horne C

Speaker 4 of 5
Francoise Baylis, Dalhousie University, Canada

Sunday, February 09 | 2:30PM - 4:30PM
Panel: Ethics of Genome Editing
Room: Van Horne C

Speaker 5 of 5
Krishanu Saha, University of Wisconsin-Madison, USA

Sunday, February 09 | 2:30PM - 4:30PM
Workshop 1: Platforms for Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 1 of 8
* Manfred Lehner, Children's Cancer Research Institute, Austria


Sunday, February 09 | 2:30PM - 4:30PM
Workshop 1: Platforms for Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 2 of 8
Carla Alicia Jaeger-Ruckstuhl, Fred Hutchinson Cancer Research Center, USA
The Role of CD27 Co-Stimulation during CAR-T Cell Generation and Immunotherapy


Sunday, February 09 | 2:30PM - 4:30PM
Workshop 1: Platforms for Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 3 of 8
Benjamin Salzer, Children's Cancer Research Institute, Austria
AvidCARs – A Novel Platform for Inducible and Combinatorial CAR Control


Sunday, February 09 | 2:30PM - 4:30PM
Workshop 1: Platforms for Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 4 of 8
Alec Wilkens, Fred Hutchinson Cancer Research Center, USA
NOTCH1 Agonism Alters Phenotype and Function of Gene Engineered CD4+ T Cells


Sunday, February 09 | 2:30PM - 4:30PM
Workshop 1: Platforms for Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 5 of 8
Michela Consonni, Fondazione Centro San Raffaele, Italy
Donor-Unrestricted Adoptive T Cell Therapy of Acute Leukemia by CD1c-Restricted TCR Transfer


Sunday, February 09 | 2:30PM - 4:30PM
Workshop 1: Platforms for Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 6 of 8
Amy N. Courtney, Baylor College of Medicine, USA
NKT Cells Suppress Metastatic Spread of Neuroblastoma by Controlling Tumor-Associated Macrophages


Sunday, February 09 | 2:30PM - 4:30PM
Workshop 1: Platforms for Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 7 of 8
Hyun Cheol Jung, Korea Advanced Institute of Science and Technology, South Korea
Elimination of Amyloid-beta Plaques by Chimeric Phagocytic Receptors


Sunday, February 09 | 2:30PM - 4:30PM
Workshop 1: Platforms for Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 8 of 8
Charlotte U. Brey, Children's Cancer Research Institute, Austria
A Conformation-Specific ON-Switch for Controlling CAR T Cells with an Orally Available Drug


Sunday, February 09 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Sunday, February 09 | 5:00PM - 7:00PM
In vivo Genome Editing
Room: Van Horne C

Speaker 1 of 6
* Fyodor D. Urnov, University of California, Berkeley, USA

Sunday, February 09 | 5:00PM - 7:00PM
In vivo Genome Editing
Room: Van Horne C

Speaker 2 of 6
James M. Wilson, University of Pennsylvania, USA
In vivo Editing to Primate Liver

Sunday, February 09 | 5:00PM - 7:00PM
In vivo Genome Editing
Room: Van Horne C

Speaker 3 of 6
Edward J. Rebar, Sangamo Therapeutics, Inc., USA
Liver Editing in vivo for Therapeutic Gene Expression

Sunday, February 09 | 5:00PM - 7:00PM
In vivo Genome Editing
Room: Van Horne C

Speaker 4 of 6
Jessica Seitzer, Intellia Therapeutics Inc., USA
Short Talk: In vivo Delivery of CRISPR/Cas9 to the Liver using Lipid Nanoparticles Enables Gene Knockout across Multiple Targets in Rodent and Non-Human Primates

Sunday, February 09 | 5:00PM - 7:00PM
In vivo Genome Editing
Room: Van Horne C

Speaker 5 of 6
David V. Schaffer, University of California, Berkeley, USA
Engineering and Evolving New Viruses for Gene Therapy and Genome Editing

Sunday, February 09 | 5:00PM - 7:00PM
In vivo Genome Editing
Room: Van Horne C

Speaker 6 of 6
Jessie R. Davis, Harvard University, USA
Short Talk: Cytosine and Adenine Base Editing of Brain, Retina, Heart, Muscle, and Liver Mediated by AAV

Sunday, February 09 | 5:00PM - 7:00PM
Engineered Hematopoietic Stem Cells for Treatment of Genetic
Diseases
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 1 of 5
* Gloria Delfanti, Fondazione Centro San Raffaele, Italy


Sunday, February 09 | 5:00PM - 7:00PM
Engineered Hematopoietic Stem Cells for Treatment of Genetic
Diseases
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 2 of 5
Marina Cavazzana, Paris Descartes University, France
Gene Therapy for Immunodeficiencies


Sunday, February 09 | 5:00PM - 7:00PM
Engineered Hematopoietic Stem Cells for Treatment of Genetic
Diseases
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 3 of 5
Alessandra Biffi, Dana-Farber Cancer Institute, Boston Children's Hospital, USA
Engineered HSCs for Correction of CNS Disorders


Sunday, February 09 | 5:00PM - 7:00PM
Engineered Hematopoietic Stem Cells for Treatment of Genetic
Diseases
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 4 of 5
Sebastian Ricardo Palacios, Massachusetts Institute of Technology, USA
Short Talk: Engineered RNAi-based Logic Circuits in Human Induced Pluripotent Stem Cells and their Differentiated Derivatives


Sunday, February 09 | 5:00PM - 7:00PM
Engineered Hematopoietic Stem Cells for Treatment of Genetic
Diseases
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 5 of 5
Esmond Lee, Stanford, USA
Short Talk: CRISPR- Based Gene Editing Enables FOXP3 Gene Repair in IPEX Patient Cells and HSPCs


Sunday, February 09 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Sunday, February 09 | 7:30PM - 10:00PM
Poster Session 1
Room: Mezzanine 2


Monday, February 10 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Monday, February 10 | 8:00AM - 11:15AM
Genome Editing as a Biology Discovery Tool
Room: Van Horne C

Speaker 1 of 9
* David R. Liu, Broad Institute, HHMI, and Harvard University, USA

Monday, February 10 | 8:00AM - 11:15AM
Genome Editing as a Biology Discovery Tool
Room: Van Horne C

Speaker 2 of 9
Kathy K. Niakan, Francis Crick Institute, UK
Towards an Understanding of Human Development Using Gene Ablation

Monday, February 10 | 8:00AM - 11:15AM
Genome Editing as a Biology Discovery Tool
Room: Van Horne C

Speaker 3 of 9
Hannah N. De Jong, Stanford University, USA
Short Talk: Deep Mutational Scanning to Identify Cardiac Disease Gene Variants

Monday, February 10 | 8:00AM - 11:15AM
Genome Editing as a Biology Discovery Tool
Room: Van Horne C

Speaker 4 of 9
Philipp Junker, Max Delbrück Center for Molecular Medicine, Germany
Massively Parallel Lineage Tracing Using CRISPR/Cas9

Monday, February 10 | 8:00AM - 11:15AM
Genome Editing as a Biology Discovery Tool
Room: Van Horne C


Coffee Break

Monday, February 10 | 8:00AM - 11:15AM
Genome Editing as a Biology Discovery Tool
Room: Van Horne C

Speaker 6 of 9
Alan Huang, Tango Therapeutics, USA
Novel Therapeutic Opportunities Identified by Synthetic Lethal Screening

Monday, February 10 | 8:00AM - 11:15AM
Genome Editing as a Biology Discovery Tool
Room: Van Horne C

Speaker 7 of 9
Andrew Ravanelli, MilliporeSigma, USA
Short Talk: Direct Capture of CRISPR Guides Enables Scalable, Multiplexed, and Multi-Omic Genetic Screens

Monday, February 10 | 8:00AM - 11:15AM
Genome Editing as a Biology Discovery Tool
Room: Van Horne C

Speaker 8 of 9
Birgit C. Schultes, IntelliaTherapeutics Inc., USA
Developing Next-Generation Engineered TCR-T Cells with CRISPR

Monday, February 10 | 8:00AM - 11:15AM
Genome Editing as a Biology Discovery Tool
Room: Van Horne C

Speaker 9 of 9
Barbara Mair, University of Toronto, Canada
Short Talk: High-Throughput Genome-Wide Phenotypic Screening via Immunomagnetic Cell Sorting Identifies QPCTL as Modulator of CD47

Monday, February 10 | 8:00AM - 11:15AM
Next Generation Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 1 of 9
* Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA


Monday, February 10 | 8:00AM - 11:15AM
Next Generation Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 2 of 9
Crystal L. Mackall, Stanford University, USA
Engineering Enhanced Potency T Cells


Monday, February 10 | 8:00AM - 11:15AM
Next Generation Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 3 of 9
Chiara Bonini, Ospedale San Raffaele, Italy
Multiple Genome Editing of Early Differentiated T Cells for Cancer Immunotherapy


Monday, February 10 | 8:00AM - 11:15AM
Next Generation Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B


Coffee Break


Monday, February 10 | 8:00AM - 11:15AM
Next Generation Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 5 of 9
Christopher A. Klebanoff, Memorial Sloan Kettering Cancer Center, USA
Targeting Solid Malignancies with 'Public' Neoantigen TCRs


Monday, February 10 | 8:00AM - 11:15AM
Next Generation Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 6 of 9
Aude G. Chapuis, Fred Hutchinson Cancer Research Center, USA
Optimizing T Cell Receptor Gene Therapy Against Solid and Liquid Tumors


Monday, February 10 | 8:00AM - 11:15AM
Next Generation Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 7 of 9
Christie Ciarlo, Altius Institute for Biomedical Sciences, USA
Short Talk: Engineering Superior T Cell Therapies without Genetic Modification


Monday, February 10 | 8:00AM - 11:15AM
Next Generation Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 8 of 9
Giedre Krenciute, St Jude Children's Research Hospital, USA
Short Talk: DNMT3a-Mediated Epigenetic Programming Limits CAR T Cell Survival and Effector Function


Monday, February 10 | 8:00AM - 11:15AM
Next Generation Immune Cell Engineering
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 9 of 9
Debattama Sen, Harvard Medical School, USA
Short Talk: Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control


Monday, February 10 | 11:15AM - 5:00PM
On Own for Lunch


Monday, February 10 | 11:15AM - 1:00PM
Poster Setup
Room: Mezzanine 2


Monday, February 10 | 1:00PM - 10:00PM
Poster Viewing
Room: Mezzanine 2


Monday, February 10 | 3:00PM - 4:30PM
Workshop: Bacterial Adaptive Immunity Anti-CRISPR
Room: Van Horne C

Speaker 1 of 6
* Yan Zhang, University of Michigan, USA

Monday, February 10 | 3:00PM - 4:30PM
Workshop: Bacterial Adaptive Immunity Anti-CRISPR
Room: Van Horne C

Speaker 2 of 6
Joseph Bondy-Denomy, University of California, San Francisco, USA
Inhibition of CRISPR-Cas9 and Cas12 with Bacteriophage Proteins

Monday, February 10 | 3:00PM - 4:30PM
Workshop: Bacterial Adaptive Immunity Anti-CRISPR
Room: Van Horne C

Speaker 3 of 6
Jan Mathony, Heidelberg University, Germany
Computational Design of Anti-CRISPR Proteins with Improved Inhibition Potency

Monday, February 10 | 3:00PM - 4:30PM
Workshop: Bacterial Adaptive Immunity Anti-CRISPR
Room: Van Horne C

Speaker 4 of 6
Jooyoung Lee, University of Massachusetts Medical School, USA
Tissue-Restricted Genome Editing in vivo Specified by MicroRNA-Repressible Anti-CRISPR Proteins

Monday, February 10 | 3:00PM - 4:30PM
Workshop: Bacterial Adaptive Immunity Anti-CRISPR
Room: Van Horne C

Speaker 5 of 6
Dominik Niopek, Heidelberg University Hospital, Germany
Switchable Anti-CRISPR Proteins for Precision Control of CRISPR-Cas9 and -12

Monday, February 10 | 3:00PM - 4:30PM
Workshop: Bacterial Adaptive Immunity Anti-CRISPR
Room: Van Horne C

Speaker 6 of 6
Jennifer R. Hamilton, University of California, Berkeley, USA
Delivery of Anti-CRISPR Proteins by Engineered Virus-Like Particles Therapeutically Protect Cells from CRISPR-Cas9 Gene Editing

Monday, February 10 | 3:30PM - 4:30PM
Workshop 2: HSC and iPSC Engineering and Therapy
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 1 of 5
* Katy Rezvani, University of Texas MD Anderson Cancer Center, USA


Monday, February 10 | 3:30PM - 4:30PM
Workshop 2: HSC and iPSC Engineering and Therapy
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 2 of 5
Linda T. Vo, University of California, San Francisco, USA
A Stem Cell Platform for Engineering Distinct T Cell Populations de novo for Immunotherapy


Monday, February 10 | 3:30PM - 4:30PM
Workshop 2: HSC and iPSC Engineering and Therapy
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 3 of 5
Brian Koss, University of Arkansas for Medical Sciences, USA
Epigenetic Control of Tumor-Infiltrating Lymphocyte Metabolic-Exhaustion


Monday, February 10 | 3:30PM - 4:30PM
Workshop 2: HSC and iPSC Engineering and Therapy
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 4 of 5
Bernhard Lehnertz, University of Montreal, Canada
Engineering of a Genetically Encoded Human Hematopoietic Stem Cell Reporter


Monday, February 10 | 3:30PM - 4:30PM
Workshop 2: HSC and iPSC Engineering and Therapy
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 5 of 5
Jose A. Vargas Asencio, Massachusetts Institute of Technology, USA
Single Cell Sequencing of Developing Liver-Like Organoids Reveals Expression Programs Associated to Germ Line Trajectories Defined by Synthetic Circuits


Monday, February 10 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Monday, February 10 | 5:00PM - 7:00PM
Translational Science of Genome Editing: Assessing Specifici
ty, Immunogenicity and Safety

Room: Van Horne C

Speaker 1 of 6
* Samantha Maragh, National institute of Standards and Technology, USA

Monday, February 10 | 5:00PM - 7:00PM
Translational Science of Genome Editing: Assessing Specifici
ty, Immunogenicity and Safety

Room: Van Horne C

Speaker 2 of 6
Julian Grünewald, Massachusetts General Hospital, USA
Advances in Identifying and Modulating the Specificities of Gene Editing Technologies

Monday, February 10 | 5:00PM - 7:00PM
Translational Science of Genome Editing: Assessing Specifici
ty, Immunogenicity and Safety

Room: Van Horne C

Speaker 3 of 6
Richard A. Morgan, Editas Medicine, USA
Application of Cpf1-Based Genome Editing for ex vivo Cell Therapy

Monday, February 10 | 5:00PM - 7:00PM
Translational Science of Genome Editing: Assessing Specifici
ty, Immunogenicity and Safety

Room: Van Horne C

Speaker 4 of 6
Krishanu Saha, University of Wisconsin-Madison, USA
Short Talk: Patient-Derived, Induced Pluripotent Stem Cells as Translational Tools to Assess Specificity, Immunogenicity, and Safety of Somatic Cell Genome Editors

Monday, February 10 | 5:00PM - 7:00PM
Translational Science of Genome Editing: Assessing Specifici
ty, Immunogenicity and Safety

Room: Van Horne C

Speaker 5 of 6
Bruce R. Conklin, University of California, San Francisco, USA
Short Talk: Modeling Therapeutic Editing in Patient-Derived iPSC Tissues

Monday, February 10 | 5:00PM - 7:00PM
Translational Science of Genome Editing: Assessing Specifici
ty, Immunogenicity and Safety

Room: Van Horne C

Speaker 6 of 6
Zuben E. Sauna, Food and Drug Administration, USA
Understanding and Navigating the Immune Responses to CRISPR-Associated Nuclease Cas9

Monday, February 10 | 5:00PM - 7:00PM
Cell Therapy for Infection and Autoimmune Diseases
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 1 of 5
* Marina Cavazzana, Paris Descartes University, France


Monday, February 10 | 5:00PM - 7:00PM
Cell Therapy for Infection and Autoimmune Diseases
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 2 of 5
Qizhi Tang, University of California, San Francisco, USA
Manipulating Tregs to Control Tolerance in Autoimmunity and Organ Transplantation


Monday, February 10 | 5:00PM - 7:00PM
Cell Therapy for Infection and Autoimmune Diseases
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 3 of 5
Bruce R. Blazar, University of Minnesota, USA
Treg Therapies in the Setting of Allogeneic HSCT


Monday, February 10 | 5:00PM - 7:00PM
Cell Therapy for Infection and Autoimmune Diseases
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 4 of 5
Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, USA
Engineering Resistance to HIV Infection


Monday, February 10 | 5:00PM - 7:00PM
Cell Therapy for Infection and Autoimmune Diseases
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 5 of 5
Megan K. Levings, University of British Columbia, Canada
CAR-Treg-Based Therapeutics


Monday, February 10 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Monday, February 10 | 7:30PM - 10:00PM
Poster Session 2
Room: Mezzanine 2


Tuesday, February 11 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Tuesday, February 11 | 8:00AM - 11:00AM
CRISPR-Based Editing of Non-Immune Cells (Joint)
Room: Van Horne A/B

Speaker 1 of 8
* Jennifer Gori, Obsidian Therapeutics, USA

Tuesday, February 11 | 8:00AM - 11:00AM
CRISPR-Based Editing of Non-Immune Cells (Joint)
Room: Van Horne A/B

Speaker 2 of 8
Jacob E. Corn, ETH in Zurich, Switzerland
How Human Cells Deal with Cas-Based Tools

Tuesday, February 11 | 8:00AM - 11:00AM
CRISPR-Based Editing of Non-Immune Cells (Joint)
Room: Van Horne A/B

Speaker 3 of 8
Scot A. Wolfe, University of Massachusetts Medical School, USA
Precise Therapeutic Gene Correction by a Simple Nuclease-Induced Double-Strand Break

Tuesday, February 11 | 8:00AM - 11:00AM
CRISPR-Based Editing of Non-Immune Cells (Joint)
Room: Van Horne A/B


Coffee Break

Tuesday, February 11 | 8:00AM - 11:00AM
CRISPR-Based Editing of Non-Immune Cells (Joint)
Room: Van Horne A/B

Speaker 5 of 8
Matthew Porteus, Stanford University School of Medicine, USA
CRISPR Editing of Human HSCs

Tuesday, February 11 | 8:00AM - 11:00AM
CRISPR-Based Editing of Non-Immune Cells (Joint)
Room: Van Horne A/B

Speaker 6 of 8
Shengdar Q. Tsai, St. Jude Children's Research Hospital, USA
Short Talk: Highly Efficient Genome Editing of Human Hematopoietic Stem Cells and Fetal Hemoglobin Induction for Sickle Cell Disease Therapy

Tuesday, February 11 | 8:00AM - 11:00AM
CRISPR-Based Editing of Non-Immune Cells (Joint)
Room: Van Horne A/B

Speaker 7 of 8
Alex Marson, University of California, San Francisco, USA
Reprogramming Human Immune Cell Circuitry

Tuesday, February 11 | 8:00AM - 11:00AM
CRISPR-Based Editing of Non-Immune Cells (Joint)
Room: Van Horne A/B

Speaker 8 of 8
Connor A. Tsuchida, University of California, Berkeley; University of California, San Francisco, USA
Short Talk: Engineering HIV-1 Virus-Like Particles for CRISPR-Cas9 Genome Engineering in Primary Human T Cells

Tuesday, February 11 | 11:00AM - 5:00PM
On Own for Lunch


Tuesday, February 11 | 11:00AM - 1:00PM
Poster Setup
Room: Mezzanine 2


Tuesday, February 11 | 1:00PM - 10:00PM
Poster Viewing
Room: Mezzanine 2


Tuesday, February 11 | 2:30PM - 4:30PM
Career Roundtable
Room: Conservatory
Interested participants must sign up at the registration desk on a first-come, first-serve basis.
Maximum attendance: 60.
Speaker 1 of 6
Samuel Haile, Kite Pharma, USA

Tuesday, February 11 | 2:30PM - 4:30PM
Career Roundtable
Room: Conservatory
Interested participants must sign up at the registration desk on a first-come, first-serve basis.
Maximum attendance: 60.
Speaker 2 of 6
Irene Jarchum, Nature, USA

Tuesday, February 11 | 2:30PM - 4:30PM
Career Roundtable
Room: Conservatory
Interested participants must sign up at the registration desk on a first-come, first-serve basis.
Maximum attendance: 60.
Speaker 3 of 6
Zuben E. Sauna, Food and Drug Administration, USA

Tuesday, February 11 | 2:30PM - 4:30PM
Career Roundtable
Room: Conservatory
Interested participants must sign up at the registration desk on a first-come, first-serve basis.
Maximum attendance: 60.
Speaker 4 of 6
Yvonne Y. Chen, University of California, Los Angeles, USA

Tuesday, February 11 | 2:30PM - 4:30PM
Career Roundtable
Room: Conservatory
Interested participants must sign up at the registration desk on a first-come, first-serve basis.
Maximum attendance: 60.
Speaker 5 of 6
Kole T. Roybal, University of California, San Francisco, USA

Tuesday, February 11 | 2:30PM - 4:30PM
Career Roundtable
Room: Conservatory
Interested participants must sign up at the registration desk on a first-come, first-serve basis.
Maximum attendance: 60.
Speaker 6 of 6
Eric J. Perkins, Addgene, USA

Tuesday, February 11 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Tuesday, February 11 | 5:00PM - 7:00PM
“Off the Shelf” Allogeneic Cell Therapies (Joint)
Room: Van Horne A/B

Speaker 1 of 6
* Crystal L. Mackall, Stanford University, USA

Tuesday, February 11 | 5:00PM - 7:00PM
“Off the Shelf” Allogeneic Cell Therapies (Joint)
Room: Van Horne A/B

Speaker 2 of 6
* Richard A. Morgan, Editas Medicine, USA

Tuesday, February 11 | 5:00PM - 7:00PM
“Off the Shelf” Allogeneic Cell Therapies (Joint)
Room: Van Horne A/B

Speaker 3 of 6
Daniel Shoemaker, Fate Therapeutics, USA
Next Generation iPSC Derived Cellular Immunotherapies for Cancer

Tuesday, February 11 | 5:00PM - 7:00PM
“Off the Shelf” Allogeneic Cell Therapies (Joint)
Room: Van Horne A/B

Speaker 4 of 6
Hanspeter Waldner, CRISPR Therapeutics, USA
Development of an Allogeneic T Cell Therapy for Oncology

Tuesday, February 11 | 5:00PM - 7:00PM
“Off the Shelf” Allogeneic Cell Therapies (Joint)
Room: Van Horne A/B

Speaker 5 of 6
Sonja Schrepfer, University of California, San Francisco, USA
Hypoimmunogenic Derivatives of Induced Pluripotent Stem Cells Evade Immune Rejection in Fully Immunocompetent Allogeneic Recipients

Tuesday, February 11 | 5:00PM - 7:00PM
“Off the Shelf” Allogeneic Cell Therapies (Joint)
Room: Van Horne A/B

Speaker 6 of 6
Theodore Roth, University of California, San Francisco, USA
Short Talk: Highly Parallel Knock-In Targeting for Genome Engineering of Cellular Immunotherapies

Tuesday, February 11 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Mezzanine 2
No registration fees are used to fund alcohol served at this function.

Tuesday, February 11 | 7:30PM - 10:00PM
Poster Session 3
Room: Mezzanine 2


Wednesday, February 12 | 7:00AM - 8:00AM
Breakfast
Room: Mezzanine 2


Wednesday, February 12 | 8:00AM - 11:00AM
DNA Repair and Genome Editing
Room: Van Horne C

Speaker 1 of 8
* Cecilia Cotta-Ramusino, Tessera Therapeutic, USA

Wednesday, February 12 | 8:00AM - 11:00AM
DNA Repair and Genome Editing
Room: Van Horne C

Speaker 2 of 8
James E. Haber, Brandeis University, USA
Understanding Cas9-Mediated Gene Targeting by Single-Strand Template Repair

Wednesday, February 12 | 8:00AM - 11:00AM
DNA Repair and Genome Editing
Room: Van Horne C

Speaker 3 of 8
Pavel Zrazhevskiy, Altius Institute for Biomedical Sciences, USA
Short Talk: Single Molecule Imaging of Nuclease-Induced Double Strand Break Repair in Human Cells

Wednesday, February 12 | 8:00AM - 11:00AM
DNA Repair and Genome Editing
Room: Van Horne C

Speaker 4 of 8
Gaelle Legube, Center for Integrative Biology, France
Transcription Coupled DNA Double Strand Break Repair: Dealing with Breaks on Transcribed Loci

Wednesday, February 12 | 8:00AM - 11:00AM
DNA Repair and Genome Editing
Room: Van Horne C


Coffee Break

Wednesday, February 12 | 8:00AM - 11:00AM
DNA Repair and Genome Editing
Room: Van Horne C

Speaker 6 of 8
Jonathan K. Watts, University of Massachusetts Medical School, USA
Chemically Modified DNA Donors for Precision Genome Editing

Wednesday, February 12 | 8:00AM - 11:00AM
DNA Repair and Genome Editing
Room: Van Horne C

Speaker 7 of 8
Albert B. Seymour, Homology Medicines, USA
AAVHSC-Mediated Genome Editing through Homologous Recombination: Applications in Liver-Mediated Diseases

Wednesday, February 12 | 8:00AM - 11:00AM
DNA Repair and Genome Editing
Room: Van Horne C

Speaker 8 of 8
Manda Arbab, Harvard University and Broad Institute, USA
Short Talk: Predictable and Precise Genome Editing Enabled by Systematic Characterization of Editing Outcomes

Wednesday, February 12 | 8:00AM - 11:15AM
Using Synthetic Biology to Enhance Safety and Efficacy of Ce
llular Therapeutics
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 1 of 10
* Alex Marson, University of California, San Francisco, USA


Wednesday, February 12 | 8:00AM - 11:15AM
Using Synthetic Biology to Enhance Safety and Efficacy of Ce
llular Therapeutics
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 2 of 10
Christine E. Brown, Beckman Research Institute, City of Hope, USA
Advancing CAR T Cell Therapy for Treatment of Brain Tumors


Wednesday, February 12 | 8:00AM - 11:15AM
Using Synthetic Biology to Enhance Safety and Efficacy of Ce
llular Therapeutics
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 3 of 10
Kole T. Roybal, University of California, San Francisco, USA
Engineering Next-Generation Immune Cell Therapies for Solid Tumors


Wednesday, February 12 | 8:00AM - 11:15AM
Using Synthetic Biology to Enhance Safety and Efficacy of Ce
llular Therapeutics
This session is from Emerging Cellular Therapies

Room: Van Horne A/B


Coffee Break


Wednesday, February 12 | 8:00AM - 11:15AM
Using Synthetic Biology to Enhance Safety and Efficacy of Ce
llular Therapeutics
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 5 of 10
Marius Wernig, Stanford University, USA
How to Make a Neuron


Wednesday, February 12 | 8:00AM - 11:15AM
Using Synthetic Biology to Enhance Safety and Efficacy of Ce
llular Therapeutics
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 6 of 10
H. Kay Chung, The Salk Institute for Biological Studies, USA
Short Talk: A Compact Synthetic Pathway Rewires Cancer Signaling to Therapeutic Effector Release


Wednesday, February 12 | 8:00AM - 11:15AM
Using Synthetic Biology to Enhance Safety and Efficacy of Ce
llular Therapeutics
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 7 of 10
Andrew Ng, University of California, San Francisco, USA
Short Talk: Modular and Tunable Biological Feedback Control Using a De Novo Protein Switch


Wednesday, February 12 | 8:00AM - 11:15AM
Using Synthetic Biology to Enhance Safety and Efficacy of Ce
llular Therapeutics
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 8 of 10
Nika Shakiba, Massachusetts Institute of Technology, USA
Short Talk: Synthetic Genetic Feedback Control Circuits to Reprogram Cell Fate


Wednesday, February 12 | 8:00AM - 11:15AM
Using Synthetic Biology to Enhance Safety and Efficacy of Ce
llular Therapeutics
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 9 of 10
Noreen Wauford, Massachusetts Institute of Technology, USA
Short Talk: Development of a Toggle Switch Based on Post-Transcriptional Regulation that Resists Epigenetic Silencing


Wednesday, February 12 | 8:00AM - 11:15AM
Using Synthetic Biology to Enhance Safety and Efficacy of Ce
llular Therapeutics
This session is from Emerging Cellular Therapies

Room: Van Horne A/B

Speaker 10 of 10
Louai Labanieh, Stanford University, USA
Short Talk: Genetically-Encoded Switches for Improving CAR-T Immunotherapy


Wednesday, February 12 | 11:00AM - 5:00PM
On Own for Lunch


Wednesday, February 12 | 4:30PM - 5:00PM
Coffee Available
Room: Van Horne Foyer


Wednesday, February 12 | 5:00PM - 6:45PM
New Genome Editing Tools
Room: Van Horne C

Speaker 1 of 5
* Scot A. Wolfe, University of Massachusetts Medical School, USA

Wednesday, February 12 | 5:00PM - 6:45PM
New Genome Editing Tools
Room: Van Horne C

Speaker 2 of 5
Erik Sontheimer, University of Massachusetts Medical School, USA
Editing Genomes with Engineered Guide RNAs and Compact, Accurate Cas9 Homologs

Wednesday, February 12 | 5:00PM - 6:45PM
New Genome Editing Tools
Room: Van Horne C

Speaker 3 of 5
Yan Zhang, University of Michigan, USA
Long-Range Genome Engineering in Human Cells with CRISPR-Cas3

Wednesday, February 12 | 5:00PM - 6:45PM
New Genome Editing Tools
Room: Van Horne C

Speaker 4 of 5
David R. Liu, Broad Institute, HHMI, and Harvard University, USA
Base Editing and Prime Editing: Genome Editing Without Double-Strand Breaks

Wednesday, February 12 | 5:00PM - 6:45PM
New Genome Editing Tools
Room: Van Horne C

Speaker 5 of 5
Peter J. Chen, Harvard University, USA
Short Talk: Programmable m6A Modification of RNA with a Cas13-Directed Methyltransferase

Wednesday, February 12 | 5:00PM - 6:45PM
Non-T Immune Cell Therapies
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 1 of 5
* Crystal L. Mackall, Stanford University, USA


Wednesday, February 12 | 5:00PM - 6:45PM
Non-T Immune Cell Therapies
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 2 of 5
Katy Rezvani, University of Texas MD Anderson Cancer Center, USA
Off-The-Shelf CAR-Engineered Cord Blood-Derived NK Cells for the Treatment of Cancer


Wednesday, February 12 | 5:00PM - 6:45PM
Non-T Immune Cell Therapies
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 3 of 5
Jeffrey S. Miller, University of Minnesota, USA
Novel Strategies to Activate and Target NK Cells as Off-The-Shelf Therapy to Treat Cancer


Wednesday, February 12 | 5:00PM - 6:45PM
Non-T Immune Cell Therapies
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 4 of 5
Leonid S. Metelitsa, Baylor College of Medicine, USA
NKT Cells as a Platform for Adoptive Cancer Immunotherapy


Wednesday, February 12 | 5:00PM - 6:45PM
Non-T Immune Cell Therapies
This session is from Emerging Cellular Therapies
Room: Van Horne A/B

Speaker 5 of 5
Eric Lagasse, University of Pittsburgh, USA
Short Talk: The Lymph Node as an Ectopic Transplantation Site for Hepatocytes


Wednesday, February 12 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Van Horne C


Wednesday, February 12 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
This session is from Emerging Cellular Therapies
Room: Van Horne A/B


Wednesday, February 12 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Alberta/New Brunswick
No registration fees are used to fund alcohol served at this function.

Wednesday, February 12 | 8:00PM - 11:00PM
Entertainment
Room: Alberta/New Brunswick
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, February 13 | 10:24AM - 10:24AM
Departure


*Session Chair
†Invited, not yet responded.